JP2024542984A - がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 - Google Patents

がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 Download PDF

Info

Publication number
JP2024542984A
JP2024542984A JP2024525065A JP2024525065A JP2024542984A JP 2024542984 A JP2024542984 A JP 2024542984A JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024542984 A JP2024542984 A JP 2024542984A
Authority
JP
Japan
Prior art keywords
compound
cancer
formula
certain embodiments
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542984A5 (enExample
Inventor
ジェイ． ブラウン，ロバート
ティー． サンズ，アーサー
Original Assignee
ニューリックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス，インコーポレイテッド filed Critical ニューリックス セラピューティクス，インコーポレイテッド
Publication of JP2024542984A publication Critical patent/JP2024542984A/ja
Publication of JP2024542984A5 publication Critical patent/JP2024542984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024525065A 2021-10-26 2022-10-25 がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 Pending JP2024542984A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263081P 2021-10-26 2021-10-26
US63/263,081 2021-10-26
US202263391671P 2022-07-22 2022-07-22
US63/391,671 2022-07-22
PCT/US2022/047767 WO2023076303A1 (en) 2021-10-26 2022-10-25 Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Publications (2)

Publication Number Publication Date
JP2024542984A true JP2024542984A (ja) 2024-11-19
JP2024542984A5 JP2024542984A5 (enExample) 2025-09-09

Family

ID=84361163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525065A Pending JP2024542984A (ja) 2021-10-26 2022-10-25 がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物

Country Status (9)

Country Link
US (1) US12377106B2 (enExample)
EP (1) EP4422630A1 (enExample)
JP (1) JP2024542984A (enExample)
KR (1) KR20240090898A (enExample)
AU (1) AU2022379494A1 (enExample)
CA (1) CA3236073A1 (enExample)
IL (1) IL312357A (enExample)
MX (1) MX2024004899A (enExample)
WO (1) WO2023076303A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113412259B (zh) 2018-10-15 2024-07-16 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
MX2022006672A (es) 2019-12-04 2022-08-08 Nurix Therapeutics Inc Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
WO2023076303A1 (en) 2021-10-26 2023-05-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099388A2 (en) 2003-03-05 2004-11-18 Proteologics, Inc. Cbl-b polypeptides, complexes and related methods
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
DK2069381T3 (da) 2006-09-13 2016-03-14 Univ Columbia Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
KR101862327B1 (ko) 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US8669251B2 (en) 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
CA2881761A1 (en) 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
EP3077388A1 (en) 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
MA42623A (fr) 2015-06-02 2018-06-20 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
CN108026088B (zh) 2015-07-17 2021-02-12 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
PL3532607T3 (pl) 2016-10-26 2024-07-01 Iovance Biotherapeutics, Inc. Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
AU2017363252B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3743063A4 (en) 2018-01-26 2021-10-20 Nurix Therapeutics, Inc. CBL-B INHIBITORS AND THEIR METHODS OF USE
JP2021512059A (ja) 2018-01-29 2021-05-13 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法
TW202513579A (zh) * 2018-06-19 2025-04-01 美商百歐恩泰美國公司 新抗原及其用途
CN113412259B (zh) * 2018-10-15 2024-07-16 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020272937B2 (en) 2019-04-09 2024-09-26 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
JP7587528B2 (ja) 2019-05-17 2024-11-20 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
CA3144450A1 (en) 2019-06-26 2020-12-30 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
AU2020320195A1 (en) 2019-07-30 2022-03-10 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
US12121540B2 (en) 2019-09-24 2024-10-22 Nurix Therapeutics, Inc. CBL inhibitors and compositions for use in adoptive cell therapy
WO2021091575A1 (en) 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
MX2022006672A (es) * 2019-12-04 2022-08-08 Nurix Therapeutics Inc Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
AU2022310182A1 (en) 2021-07-14 2024-02-01 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with diminished imid activity
EP4373493A1 (en) * 2021-07-23 2024-05-29 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with enhanced imid activity
WO2023076303A1 (en) 2021-10-26 2023-05-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Also Published As

Publication number Publication date
KR20240090898A (ko) 2024-06-21
MX2024004899A (es) 2024-05-24
WO2023076303A1 (en) 2023-05-04
US12377106B2 (en) 2025-08-05
US20230149416A1 (en) 2023-05-18
IL312357A (en) 2024-06-01
CA3236073A1 (en) 2023-05-04
EP4422630A1 (en) 2024-09-04
AU2022379494A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
EP4069237B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP7745679B2 (ja) 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用
JP2024527567A (ja) Ｋｒａｓの阻害剤としての三環式化合物
US10954240B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA2907751C (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors for the treatment of cancer
US12377106B2 (en) Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
WO2020100027A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
JP2019518059A (ja) ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体
CA2942751A1 (en) Macrocylic pyridine derivatives
CA2942636A1 (en) Macrocylic pyrimidine derivatives
WO2021224818A1 (en) Isoindolone compounds as hpk1 inhibitors
CN108699080B (zh) 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
CN118475352A (zh) 用于治疗和预防癌症以及用于降解btk的哌啶基吡嗪-甲酰胺类化合物
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
TWI692476B (zh) 環丁基-咪唑啶酮化合物
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
TW202602873A (zh) 新穎降解劑化合物及其用途
TW202421153A (zh) 細胞週期蛋白依賴性激酶７的抑制劑
HK40058692A (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
OA20485A (en) IMIDAZO[4,5-C]pyridine derivatives as tolllike receptor agonsits
HK40029219A (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
OA20310A (en) 2,3-dihydro-1H-pyrrolo[3,4-C] pyridin-1one derivatives as HPK1 inhibitors for the treatment of cancer.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250901